These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 38219335)

  • 1. The effects of semaglutide, empagliflozin and their combination on the kidney sodium signal from magnetic resonance imaging: A prespecified, secondary analysis from a randomized, clinical trial.
    Gullaksen S; Vernstrøm L; Sørensen SS; Ringgaard S; Laustsen C; Birn H; Funck KL; Poulsen PL; Laugesen E
    J Diabetes Complications; 2024 Feb; 38(2):108673. PubMed ID: 38219335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Separate and combined effects of semaglutide and empagliflozin on kidney oxygenation and perfusion in people with type 2 diabetes: a randomised trial.
    Gullaksen S; Vernstrøm L; Sørensen SS; Ringgaard S; Laustsen C; Funck KL; Poulsen PL; Laugesen E
    Diabetologia; 2023 May; 66(5):813-825. PubMed ID: 36746803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of Once-Weekly Semaglutide vs Empagliflozin Added to Metformin in Type 2 Diabetes: Patient-Level Meta-analysis.
    Lingvay I; Capehorn MS; Catarig AM; Johansen P; Lawson J; Sandberg A; Shaw R; Paine A
    J Clin Endocrinol Metab; 2020 Dec; 105(12):e4593-604. PubMed ID: 32827435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Separate and combined effects of empagliflozin and semaglutide on vascular function: A 32-week randomized trial.
    Vernstrøm L; Gullaksen S; Sørensen SS; Funck KL; Laugesen E; Poulsen PL
    Diabetes Obes Metab; 2024 May; 26(5):1624-1635. PubMed ID: 38240066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial.
    Rodbard HW; Rosenstock J; Canani LH; Deerochanawong C; Gumprecht J; Lindberg SØ; Lingvay I; Søndergaard AL; Treppendahl MB; Montanya E;
    Diabetes Care; 2019 Dec; 42(12):2272-2281. PubMed ID: 31530666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Semaglutide combined with empagliflozin vs. monotherapy for non-alcoholic fatty liver disease in type 2 diabetes: Study protocol for a randomized clinical trial.
    Lin YH; Zhang ZJ; Zhong JQ; Wang ZY; Peng YT; Lin YM; Zhang HP; Tian JQ
    PLoS One; 2024; 19(5):e0302155. PubMed ID: 38701096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of semaglutide and empagliflozin on oxygenation, vascular autoregulation, and central thickness of the retina in people with type 2 diabetes: A prespecified secondary analysis of a randomised clinical trial.
    Gullaksen S; Vernstrøm L; Sørensen SS; Funck KL; Petersen L; Bek T; Poulsen PL; Laugesen E
    J Diabetes Complications; 2023 May; 37(5):108472. PubMed ID: 37062189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessing the cost-effectiveness of a once-weekly GLP-1 analogue versus an SGLT-2 inhibitor in the Spanish setting: Once-weekly semaglutide versus empagliflozin.
    Gorgojo-Martínez JJ; Malkin SJP; Martín V; Hallén N; Hunt B
    J Med Econ; 2020 Feb; 23(2):193-203. PubMed ID: 31613199
    [No Abstract]   [Full Text] [Related]  

  • 9. Albuminuria-lowering effect of adding semaglutide on top of empagliflozin in individuals with type 2 diabetes: A randomized and placebo-controlled study.
    Sivalingam S; Wasehuus VS; Rotbain Curovic V; Blond MB; Hansen TW; Persson F; Rossing P
    Diabetes Obes Metab; 2024 Jan; 26(1):54-64. PubMed ID: 37722966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduction of estimated fluid volumes following initiation of empagliflozin in patients with type 2 diabetes and cardiovascular disease: a secondary analysis of the placebo-controlled, randomized EMBLEM trial.
    Tanaka A; Shimabukuro M; Teragawa H; Okada Y; Takamura T; Taguchi I; Toyoda S; Tomiyama H; Ueda S; Higashi Y; Node K;
    Cardiovasc Diabetol; 2021 Jun; 20(1):105. PubMed ID: 34183012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial.
    Cherney DZI; Zinman B; Inzucchi SE; Koitka-Weber A; Mattheus M; von Eynatten M; Wanner C
    Lancet Diabetes Endocrinol; 2017 Aug; 5(8):610-621. PubMed ID: 28666775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Usefulness of Empagliflozin Versus Oral Semaglutide for Prevention of Cardiovascular Mortality in Patients With Type 2 Diabetes Mellitus.
    Hammerman A; Moore CM; Aboalhasan E; Azuri J; Arbel R
    Am J Cardiol; 2022 May; 170():128-131. PubMed ID: 35197207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of empagliflozin versus weekly semaglutide as add-on therapy for Type 2 diabetes.
    Zupa MF; Codario RA; Smith KJ
    J Comp Eff Res; 2021 Oct; 10(15):1133-1141. PubMed ID: 34490786
    [No Abstract]   [Full Text] [Related]  

  • 14. The Cost-Effectiveness of Oral Semaglutide in Spain: A Long-Term Health Economic Analysis Based on the PIONEER Clinical Trials.
    Franch-Nadal J; Malkin SJP; Hunt B; Martín V; Gallego Estébanez M; Vidal J
    Adv Ther; 2022 Jul; 39(7):3180-3198. PubMed ID: 35553372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The cost-effectiveness of oral semaglutide versus empagliflozin in Type 2 diabetes in Denmark.
    Ehlers LH; Lamotte M; Ramos MC; Sandgaard S; Holmgaard P; Frary EC; Ejskjaer N
    J Comp Eff Res; 2022 Jan; 11(1):29-37. PubMed ID: 34841893
    [No Abstract]   [Full Text] [Related]  

  • 16. Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease.
    Wanner C; Lachin JM; Inzucchi SE; Fitchett D; Mattheus M; George J; Woerle HJ; Broedl UC; von Eynatten M; Zinman B;
    Circulation; 2018 Jan; 137(2):119-129. PubMed ID: 28904068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical review of the efficacy and safety of oral semaglutide in patients with type 2 diabetes compared with other oral antihyperglycemic agents and placebo.
    Lavernia F; Blonde L
    Postgrad Med; 2020 Nov; 132(sup2):15-25. PubMed ID: 32815436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short-term cost-effectiveness of oral semaglutide for the treatment of type 2 diabetes mellitus in the United States.
    Cui J; Klepser DG; McAdam-Marx C
    J Manag Care Spec Pharm; 2021 Jul; 27(7):840-845. PubMed ID: 34185562
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial.
    Verma S; Mazer CD; Yan AT; Mason T; Garg V; Teoh H; Zuo F; Quan A; Farkouh ME; Fitchett DH; Goodman SG; Goldenberg RM; Al-Omran M; Gilbert RE; Bhatt DL; Leiter LA; Jüni P; Zinman B; Connelly KA
    Circulation; 2019 Nov; 140(21):1693-1702. PubMed ID: 31434508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
    Wanner C; Inzucchi SE; Lachin JM; Fitchett D; von Eynatten M; Mattheus M; Johansen OE; Woerle HJ; Broedl UC; Zinman B;
    N Engl J Med; 2016 Jul; 375(4):323-34. PubMed ID: 27299675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.